Masters of Longevity - The Pulse

Peter Attia Blog20 Jun 2026
Can AI models reason like clinicians? (Peter Attia Blog)

Can AI models reason like clinicians?

Assess whether frontier large language models match clinicians' reasoning by examining a workflow-focused benchmark and its implications for clinical use.

Key takeaways
  • Twenty-one frontier LLMs were evaluated on twenty-nine MSD Manual clinical vignettes.
  • Each vignette preserved sequential clinical context and was run in triplicate for scoring.
  • PrIME-LLM scores compute a normalized polygonal area across five clinical reasoning domains.
PR Newswire20 Jun 2026
AINew 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway (PR Newswire)

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

Examine how AI chat engines cite drugmakers compared with where pharmaceutical companies spend on direct-to-consumer advertising, revealing visibility mismatches.

Key takeaways
  • 5W found AI citation shares via 60+ patient prompts across five major engines.
  • Eli Lilly holds an estimated 12.5% AI citation share.
  • Novo Nordisk holds an estimated 11.5% AI citation share.
MoL Event Pick
The Longevity Show 2026 (London, United Kingdom)

The Longevity Show 2026

26. JUN 2026 - 27. JUN 2026 - London, United KingdomExpo

The UK’s first longevity festival, helping you discover what really works for living healthier, longer. Testing, workouts, speakers & more.

Neuroscience News19 Jun 2026
Disrupted Neuronal Microexons Drive Hyperarousal and Insomnia (Neuroscience News)

Disrupted Neuronal Microexons Drive Hyperarousal and Insomnia

Neuronal microexons feature in an accessible science piece unpacking new research on tiny neuronal gene fragments and their broader neurobiological implications.

Key takeaways
  • New study found that altered neuronal microexons cause hyperarousal and insomnia in zebrafish.
  • Researchers discovered that abnormal alternative splicing spikes cAMP signaling.
  • Because this pathway is evolutionarily conserved and linked to human microexon mutations.
traderVC19 Jun 2026
Traded: Venture Capital 🦄 on Instagram: "Houdini Bio has emerged from stealth with $1.95 million in pre-seed funding led by SCVC, with participation from Deep...

Traded: Venture Capital 🦄 on Instagram: "Houdini Bio has emerged from stealth with $1.95 million in pre-seed funding led by SCVC, with participation from Deep Science Ventures and Cambridge Enterprise Ventures, to develop a DNA engineering platform designed to improve the durability and effectiveness of gene therapies. Founded in 2025, the British biotech startup combines machine learning with research into cellular DNA silencing mechanisms to help therapeutic genes evade biological defenses that can reduce treatment efficacy. The company says its platform can increase gene expression by more than tenfold compared to existing approaches, with potential applications across conditions including cystic fibrosis, haemophilia, cancer, dementia, and inherited blindness. FOUNDERS: Jonathan Cohen-Gold & Lee Dunham INVESTORS: SCVC, Deep Science Ventures & Cambridge Enterprise Ventures ROUND: Pre-Seed AMOUNT: $1,950,000 HQ: Cambridge, United Kingdom #VentureCapital #HoudiniBio #JonathanCohenGold #SCVC #DeepScienceVentures TradedVC"

Startup profile focusing on founders, financing and scientific strategy behind a biotech's debut, offering context for investors and scientific readers.

Key takeaways
  • Houdini Bio secured $1.95 million pre-seed funding to pursue therapies for cystic fibrosis.
  • Houdini Bio is developing a DNA-engineering platform combining machine learning with DNA-silencing research.
  • Company reports the platform increases gene expression more than tenfold versus current approaches.